Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 15/20 | 0.70 |
| ▸ | CPT2 | P23786 | 1/20 | 0.52 |
| ▸ | CPT1A | P50416 | 1/20 | 0.52 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21931134 | 0.82 | ACLY (1.00) | ACLY | |
| SCHEMBL7150197 | 0.72 | ALDH1A1 (0.59) | ACLYCPT2CPT1ACPT1BLMNA | |
| SCHEMBL21999830 | 0.71 | HDAC1 (0.50) | ACLYSCN9A | |
| SCHEMBL18013245 | 0.71 | ACLY (0.49) | ACLYSCN9A | |
| SCHEMBL21930841 | 0.71 | ACLY (1.00) | ACLY | |
| SCHEMBL3727556 | 0.70 | ACLY (0.57) | ACLYCPT2CPT1ACPT1BLMNA | |
| SCHEMBL7990845 | 0.70 | FLT1 (0.65) | SCN9AFLT1FLT4KDRLMNA | |
| SCHEMBL2489186 | 0.69 | SMN1; SMN2 (0.53) | ACLYMAPT | |
| SCHEMBL3724899 | 0.69 | FABP4 (0.59) | ACLY | |
| SCHEMBL24102246 | 0.69 | KMT2A (0.61) | ACLYLMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885CPT2 171/4885CPT1A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.